OBJECTIVE: To evaluate the effect of this plant as adjunctive therapy on () eradication. METHODS: The plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with infection were randomized to receive Rech. f. & Esfand () or placebo capsules for two weeks. All the patients in both groups received clarithromycin-based triple therapy. Both intention to treat and per protocol analyses were performed. Eradication rates, treatment side effects, and medication compliance were evaluated in both groups. RESULTS: H. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of was significantly higher in group compared with that in the placebo group for per protocol analysis (84.62%, = 0.026) but not for intention to treat one (65.31%, 0.252). There were no significant differences between the two groups regarding the frequencies of the medications side effects and the patients with poor compliance. CONCLUSION: The use of as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve eradication rate.